Background: The effect of biochemical aspirin resistance (BAR) on ischemic stroke has not been well established. Early recurrent ischemic lesions (ERILs) on diffusion-weighted imaging (DWI) are proposed as potential surrogate markers of clinically recurrent stroke. Methods: We included 117 consecutive patients who (1) were admitted within 24 h of symptom onset; (2) had an ischemic stroke confirmed by DWI; (3) underwent follow-up DWI within seven days after onset, and (4) received aspirin treatment. BAR was measured using the VerifyNow® Aspirin Assay. We analyzed the associations between BAR and any ERILs (overall ERILs), and between BAR and ERILs occurring outside the vascular territories of index stroke (distant ERILs). Results: BAR was observed in 16 (13.7%) patients. Overall ERILs were detected in 34 (29.1%), and distant ERILs in 10 (8.5%) patients. Patients with BAR were more likely to develop ERILs, but the association was not significant (OR 2.13; 95% CI 0.72–6.29; p = 0.234). However, BAR was independently related to distant ERILs by logistic regression analysis (OR 6.01; 95% CI 1.29–28.09; p = 0.023). Conclusions: BAR was associated with distant ERILs but not with overall ERILs during the first week after ischemic stroke.

Keywords:
Aspirin, Stroke, Magnetic resonance imaging
1.
Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Sacco RL, Schwamm LH: Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:1647–1652.
2.
Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
3.
Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-anaylsis. BMJ 2008;336:195–198.
4.
Zytkiewicz M, Giełwanowska L, Wojtasińska E, Psuja P, Zawilska K: Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn 2008;118:727–733.
5.
Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM: A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci 2008;15:1204–1209.
6.
Hankey GJ, Eikelboom JW: Aspirin resistance. BMJ 2004;328:477–479.
7.
Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230–235.
8.
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650–1655.
9.
Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961–965.
10.
Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO: Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998;50:208–216.
11.
Kang DW, Latour LL, Chalela JA, Dambrosia J, Warach S: Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann Neurol 2003;54:66–74.
12.
Kang DW, Latour LL, Chalela JA, Dambrosia JA, Warach S: Early and late recurrence of ischemic lesion on MRI: evidence for a prolonged stroke-prone state? Neurology 2004;63:2261–2265.
13.
Kang DW, Lattimore SU, Latour LL, Warach S: Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol 2006;63:1730–1733.
14.
Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, Domanski M: Frequency of aspirin resistance in a community hospital. Am J Cardiol 2006;98:577–579.
15.
Cho AH, Kim JS, Jeon SB, Kwon SU, Lee DH, Kang DW: Mechanism of multiple infarcts in multiple cerebral circulations on diffusion-weighted imaging. J Neurol 2007;254:924–930.
16.
Tatu L, Moulin T, Bogousslavsky J, Duvernoy H: Arterial territories of the human brain: cerebral hemispheres. Neurology 1998;50:1699–1708.
17.
Tatu L, Moulin T, Bogousslavsky J, Duvernoy H: Arterial territories of human brain: brainstem and cerebellum. Neurology 1996;47:1125–1135.
18.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd; TOAST Investigators: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993;24:35–41.
19.
Kang DW, Yoo SH, Chun S, Kwon KY, Kwon SU, Koh JY, Kim JS: Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke. Stroke 2009;40:1653–1658.
20.
Iguchi Y, Kimura K, Kobayashi K, Ueno Y, Shibazaki K, Inoue T: Microembolic signals at 48 hours after stroke onset contribute to new ischaemia within a week. J Neurol Neurosurg Psychiatry 2008;79:253–259.
21.
Droste DW, Knapp J, Freund M, Nágy I, Schulte V, Schomacher G, Csiba L, Ringelstein EB: Diffusion weighted MRI imaging and MES detection in the assessment of stroke origin. Neurol Res 2007;29:480–484.
22.
Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB: Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection. Circulation 2005;111:2233–2240.
23.
Uchiyama S, Nakamura T, Yamazaki M, Kimura Y, Iwata M: New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006;21(suppl 1):7–16.
24.
Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J: Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175–178.
25.
Undas A, Brummel K, Musial J, Mann KG, Szczeklik A: PlA2 polymorphism of β3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666–2672.
26.
Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K: PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997;349:385–388.
27.
Englyst NA, Horsfield G, Kwan J, Byrne CD: Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab 2008;28:1196–1203.
28.
Buerke M, Pittroff W, Meyer J, Darius H: Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995;130:465–472.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.